MENU
THNR
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

THNR stock forecast, quote, news & analysis

The investment seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index... Show more

Category: #Health
THNR
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for THNR with price predictions
Aug 21, 2026

Aroon Indicator for THNR shows an upward move is likely

THNR's Aroon Indicator triggered a bullish signal on July 31, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 84 similar instances where the Aroon Indicator showed a similar pattern. In of the 84 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 06, 2026. You may want to consider a long position or call options on THNR as a result. In of 33 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for THNR just turned positive on August 07, 2026. Looking at past instances where THNR's MACD turned positive, the stock continued to rise in of 21 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where THNR advanced for three days, in of 123 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where THNR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

THNR broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Pfizer (NYSE:PFE), Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Industry description

The investment seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index. The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, including dual GLP-1 agonists and analogs. The fund is non-diversified.

Market Cap

The average market capitalization across the Amplify Weight Loss Drug & Treatment ETF ETF is 178.63B. The market cap for tickers in the group ranges from 604.95M to 1.12T. LLY holds the highest valuation in this group at 1.12T. The lowest valued company is ALT at 604.95M.

High and low price notable news

The average weekly price growth across all stocks in the Amplify Weight Loss Drug & Treatment ETF ETF was 20%. For the same ETF, the average monthly price growth was 25%, and the average quarterly price growth was 116%. HIMS experienced the highest price growth at 20%, while ROG experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the Amplify Weight Loss Drug & Treatment ETF ETF was 51%. For the same stocks of the ETF, the average monthly volume growth was 35% and the average quarterly volume growth was -16%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 41
P/E Growth Rating: 54
Price Growth Rating: 34
SMR Rating: 65
Profit Risk Rating: 66
Seasonality Score: -25 (-100 ... +100)
View a ticker or compare two or three
THNR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
Amplify ETF Trust3250 Lacey Road, Suite 130Downers Grove
Phone
(630) 464-7600
Web
N/A